| Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model AMM Eggermont, D Bellomo, SM Arias-Mejias, E Quattrocchi, ... European Journal of Cancer 140, 11-18, 2020 | 38 | 2020 |
| Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary I Johansson, D Tempel, JT Dwarkasing, B Rentroia-Pacheco, J Mattsson, ... European Journal of Surgical Oncology 48 (2), 320-325, 2022 | 22 | 2022 |
| Validation of CP‐GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a US cohort study A Yousaf, FJ Tjien‐Fooh, B Rentroia‐Pacheco, E Quattrocchi, A Kobic, ... International journal of dermatology 60 (7), 851-856, 2021 | 22 | 2021 |
| Trypanosoma brucei triggers a broad immune response in the adipose tissue H Machado, T Bizarra-Rebelo, M Costa-Sequeira, S Trindade, T Carvalho, ... PLoS pathogens 17 (9), e1009933, 2021 | 18 | 2021 |
| Risk factors for metastatic cutaneous squamous cell carcinoma: Refinement and replication based on 2 nationwide nested case-control studies S Tokez, ZC Venables, LM Hollestein, H Qi, EM Bramer, ... Journal of the American Academy of Dermatology 87 (1), 64-71, 2022 | 12 | 2022 |
| Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I–II melanoma patients at risk of disease relapse EEAP Mulder, I Johansson, DJ Grünhagen, D Tempel, ... Cancers 14 (12), 2854, 2022 | 11 | 2022 |
| Clinicopathologic models predicting non‐sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node? B Rentroia‐Pacheco, FJ Tjien‐Fooh, E Quattrocchi, A Kobic, R Wever, ... Journal of surgical oncology 125 (3), 516-524, 2022 | 5 | 2022 |
| Personalised decision making to predict absolute metastatic risk in cutaneous squamous cell carcinoma: development and validation of a clinico-pathological model B Rentroia-Pacheco, S Tokez, EM Bramer, ZC Venables, ... EClinicalMedicine 63, 2023 | 2 | 2023 |
| Independent validation study of a CP-GEP model (Merlin Assay) to identify patients with melanoma who can safely forgo sentinel lymph node biopsy I Johansson, D Tempel, JT Dwarkasing, B Rentroia-Pacheco, J Mattsson, ... | 2* | |
| Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I-II melanoma patients at risk for disease relapse E Mulder, I Johansson, D Grünhagen, D Tempel, B Rentroia-Pacheco, ... European Journal of Surgical Oncology 49 (2), e33-e34, 2023 | 1 | 2023 |
| Efficient study design for the discovery of a gene expression signature predicting metastasis in cutaneous squamous cell carcinoma B Rentroia-Pacheco, L Pozza, YT Chen, D Huigh, CJ Eggermont, ... Cancer Research 84 (6_Supplement), 4869-4869, 2024 | | 2024 |
| Avoiding the pitfalls in developing and validating prediction models for rare outcomes in nested case-control B Rentroia-Pacheco, D Bellomo, IMM Lakeman, M Wakkee, LM Hollestein, ... Cancer Research 84 (6_Supplement), 4868-4868, 2024 | | 2024 |
| Beyond staging systems in cutaneous squamous cell carcinoma: Validation of two thresholds for a model-estimated metastatic risk OFM Steijlen, L Pozza, B Rentroia-Pacheco, CJ Eggermont, D Bellomo, ... Cancer Research 84 (6_Supplement), 3463-3463, 2024 | | 2024 |
Domenico BellomoDirector BioinformaticsVerified email at skylinedx.com
